Please enable Javascript
Ajai Chari, MD
Articles by Ajai Chari, MD
Myeloma Panel Discusses 3 FDA-Approved Bispecific Agents: Talquetamab, Teclistamab, Elranatamab
Thomas Martin, MD
Video Insights
|
September 19, 2023
The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.
View More
Practical Treatment Considerations for the Use of Talquetamab in Patients with Relapsed or Refractory MM
Larysa Sanchez, MD
Myeloma
|
May 2, 2023
This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.
Read More
Ajai Chari, MD, Discusses the MonumenTAL-1 Study
Ajai Chari, MD
Video Insights
|
December 27, 2022
Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.
View More